Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive and palliative care

2211 - Use of chemotherapy near the end of life for solid cancers: What factors matter?


08 Oct 2016


Supportive and palliative care


Philippe Rochigneux


Annals of Oncology (2016) 27 (6): 455-461. 10.1093/annonc/mdw384


P. Rochigneux1, J.L. Raoul1, L. Morin2

Author affiliations

  • 1 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 2 Aging Research Center, Karolinska Institutet, 113 30 Stockholm - Stockholm/SE


Abstract 2211


Use of chemotherapy near the end of life (EOL) for solid cancer patients is usually ineffective and toxic. Data about the factors associated with its use remain scarce, especially in Europe.


We designed a nationwide, register-based study including all hospitalized patients aged ≥20 years who died with metastatic solid tumors in France between 2010 and 2013. Multivariate analyses were performed to identify patients, tumor and facility level characteristics associated with chemotherapy use. Specific sub-analyses were also computed to investigate the role of the supposed tumors' chemosensitivity (defined by the tumors response rate to first line chemotherapy).


279,846 metastatic solid cancers were included. Chemotherapy rates near the EOL were 39.1% (last 3 month), 19.5% (last month), 11.3% (last 2 weeks). During their last month of life, 6.6% of patients started or resumed a chemotherapy regimen. In multivariate analysis, female sex (OR = 0.96, 0.93-0.98), older age (OR = 0.70, 0.69-0.71 for each 10-year increase) and higher number of chronic comorbidities (OR = 0.83, 0.82-0.84) were independently associated with lower rates of chemotherapy. Tumor chemosensitivity was positively associated with the odds of receiving chemotherapy during the last month of life (OR= 1.21, 1.18-1.25). Patients with a cancer for which a major therapeutic innovation occurred between 2005-2010 were also more likely to receive chemotherapy (OR = 1.17, 1.14-1.20). Compared with university hospitals, patients who died in for-profit hospitals (OR= 1.40, 1.34-1.45), and comprehensive cancer centers (OR= 1.43, 1.36-1.50) were more likely to receive chemotherapy. Finally, high-volume centers and hospitals without palliative care units reported greater-than-average rates of chemotherapy near the end of life.


Chemotherapy rates near the EOL for metastatic solid cancers patients are high, especially in young patients, treated in high-volume centers, without palliative care unit. To decrease the aggressiveness of EOL treatments, there is an urgent need to develop early palliative care, to reinforce supportive care training for oncologist, and to implement clear EOL care guidelines.

Clinical trial identification

Legal entity responsible for the study

ATIH : Agence technique de l'information sur l'hospitalisation


Paoli Calmette Institute, Marseille Aging Research Center, Karolinska Institutet, Stockholm


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings